Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

205.75 -5.90 (-2.79%)
Streaming Delayed Price Updated: 11:44 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
From Natera, Inc.
Via Business Wire
News headline image
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
News headline image
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
From Natera, Inc.
Via Business Wire
News headline image
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Reproductive Health Assets from Invitae
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
News headline image
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
News headline image
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
News headline image
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
News headline image
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Third Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in November Investor Conferences
From Natera, Inc.
Via Business Wire
News headline image
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
From Natera, Inc.
Via Business Wire
News headline image
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter 2023 Results on November 8
From Natera, Inc.
Via Business Wire
News headline image
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.